Published in Hepatology on January 01, 2005
Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med (2008) 6.67
Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med (2009) 3.76
Mortality associated with low serum sodium concentration in maintenance hemodialysis. Am J Med (2011) 2.85
MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut (2007) 2.09
Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transpl (2011) 1.67
Serum sodium, renal function, and survival of patients with end-stage liver disease. J Hepatol (2010) 1.62
Stage of cirrhosis predicts the risk of liver-related death in patients with low Model for End-Stage Liver Disease scores and cirrhosis awaiting liver transplantation. Liver Transpl (2014) 1.48
Kidney, pancreas and liver allocation and distribution in the United States. Am J Transplant (2012) 1.24
Model for end-stage liver disease: end of the first decade. Clin Liver Dis (2011) 1.20
Important predictor of mortality in patients with end-stage liver disease. Clin Mol Hepatol (2013) 1.15
Diagnosis and management of hyponatremia in acute illness. Curr Opin Crit Care (2008) 1.10
Prioritization for liver transplantation. Nat Rev Gastroenterol Hepatol (2010) 1.05
Hyponatraemia: more than just a marker of disease severity? Nat Rev Nephrol (2012) 0.99
Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology (2009) 0.99
Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation. BMC Gastroenterol (2009) 0.97
Using an Electronic Medical Records Database to Identify Non-Traditional Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol (2016) 0.96
Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease. Aliment Pharmacol Ther (2009) 0.95
Evaluation of a scoring system for assessing prognosis in pediatric acute liver failure. Clin Gastroenterol Hepatol (2008) 0.91
Evaluation and management of patients with refractory ascites. World J Gastroenterol (2009) 0.89
Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANONIC study. Crit Care (2014) 0.89
Overview of the indications and contraindications for liver transplantation. Cold Spring Harb Perspect Med (2014) 0.87
Alkaline phosphatase: the next independent predictor of the poor 90-day outcome in alcoholic hepatitis. Biomed Res Int (2013) 0.86
Improving survival in decompensated cirrhosis. Int J Hepatol (2012) 0.86
Impact of pretransplant hepatic encephalopathy on liver posttransplantation outcomes. Int J Hepatol (2013) 0.85
Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. Support Care Cancer (2015) 0.85
Factors prognostic of survival in patients awaiting liver transplantation for end-stage liver disease. Dig Dis Sci (2007) 0.85
New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt. Clin Gastroenterol Hepatol (2009) 0.83
Hyponatraemia and cirrhosis. Gastroenterol Rep (Oxf) (2014) 0.82
Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. Hepat Med (2013) 0.82
Plasma fibroblast growth factor 23 concentration is increased and predicts mortality in patients on the liver-transplant waiting list. PLoS One (2013) 0.79
Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure. Mol Med Rep (2014) 0.78
Advances in liver transplantation allocation systems. World J Gastroenterol (2016) 0.78
Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose. Saudi J Gastroenterol (2011) 0.77
Liver transplantation in adults: Choosing the appropriate timing. World J Gastrointest Pharmacol Ther (2012) 0.77
Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B. World J Gastroenterol (2008) 0.76
Comparison of four models for end-stage liver disease in evaluating the prognosis of cirrhosis. World J Gastroenterol (2008) 0.75
Current Status of Liver Allocation in the United States. Gastroenterol Hepatol (N Y) (2016) 0.75
Moderate hyperkalemia in hospitalized patients with cirrhotic ascites indicates a poor prognosis. Scand J Gastroenterol (2013) 0.75
MELD and serum sodium. Hepatology (2005) 0.75
Profound hyponatremia in cirrhosis: a case report. Cases J (2010) 0.75
Impact of MELD Allocation System on Waiting List and Early Post-Liver Transplant Mortality. PLoS One (2016) 0.75
Prognostic Significance of Ascites and Serum Sodium in Patients with Low Meld Scores. Med Arch (2016) 0.75
Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis. World J Hepatol (2014) 0.75
Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach. Dig Dis Sci (2017) 0.75
Ascites Neutrophil Gelatinase-Associated Lipocalin Identifies Spontaneous Bacterial Peritonitis and Predicts Mortality in Hospitalized Patients with Cirrhosis. Dig Dis Sci (2017) 0.75
Clinical Features of Refractory Ascites in Outpatients. Clinics (Sao Paulo) (2017) 0.75
Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterol Rep (Oxf) (2017) 0.75
Evaluation of Adrenal Function in Nonhospitalized Patients with Cirrhosis. Can J Gastroenterol Hepatol (2017) 0.75
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Age affects outcomes in chronic kidney disease. J Am Soc Nephrol (2007) 5.36
Association of journal quality indicators with methodological quality of clinical research articles. JAMA (2002) 5.13
Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function. N Engl J Med (2015) 5.12
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26
Burden of liver disease in the United States: summary of a workshop. Hepatology (2002) 4.00
Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med (2008) 3.64
Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med (2008) 3.57
SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell (2011) 3.33
Transfusion-related acute lung injury: incidence and risk factors. Blood (2011) 3.12
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (2009) 3.12
Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl (2014) 3.11
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
Physician predictors of mammographic accuracy. J Natl Cancer Inst (2005) 2.72
Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology (2006) 2.62
A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl (2005) 2.56
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr (2010) 2.47
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol (2010) 2.41
Changes in stress, eating, and metabolic factors are related to changes in telomerase activity in a randomized mindfulness intervention pilot study. Psychoneuroendocrinology (2011) 2.37
Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med (2007) 2.36
Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest (2008) 2.35
Geography matters: relationships among urban residential segregation, dialysis facilities, and patient outcomes. Ann Intern Med (2007) 2.33
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl (2002) 2.28
Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer (2014) 2.26
Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology (2005) 2.24
Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis (2013) 2.23
The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol (2007) 2.19
Effect of emergency department crowding on time to antibiotics in patients admitted with community-acquired pneumonia. Ann Emerg Med (2007) 2.18
White/black racial differences in risk of end-stage renal disease and death. Am J Med (2009) 2.16
Predictors of publication: characteristics of submitted manuscripts associated with acceptance at major biomedical journals. Med J Aust (2006) 2.14
Improving liver allocation: MELD and PELD. Am J Transplant (2004) 2.14
Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology (2012) 2.10
Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog (2013) 2.06
Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr (2008) 2.05
Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology (2006) 2.04
Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS (2005) 2.03
Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl (2002) 2.03
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med (2003) 2.02
Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr (2007) 1.98
HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.94
Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med (2007) 1.94
The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr (2008) 1.94
A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology (2008) 1.93
Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis (2011) 1.90
The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant (2005) 1.90
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl (2011) 1.85
Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis (2010) 1.84
Frequency of trigeminal nerve injuries following third molar removal. J Oral Maxillofac Surg (2005) 1.84
Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. Am J Epidemiol (2003) 1.82
Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2. Am J Kidney Dis (2003) 1.82
The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Natl Acad Sci U S A (2013) 1.80
Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology (2008) 1.74
Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis (2002) 1.72
Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis (2011) 1.70
Low ankle-brachial index associated with rise in creatinine level over time: results from the atherosclerosis risk in communities study. Arch Intern Med (2005) 1.69
Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS (2009) 1.68
High rates of sustained smoking cessation in women hospitalized with cardiovascular disease: the Women's Initiative for Nonsmoking (WINS). Circulation (2004) 1.68
Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr (2010) 1.67
Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant (2003) 1.65
Comparison of dual-energy X-ray absorptiometry and magnetic resonance imaging-measured adipose tissue depots in HIV-infected and control subjects. Am J Clin Nutr (2008) 1.63
Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2009) 1.63
Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis (2007) 1.62
Predictors associated with terminal renal function in deceased organ donors in the intensive care unit. Anesthesiology (2009) 1.60
Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J Hepatol (2010) 1.60
Interactions of fluorochemicals with rat liver fatty acid-binding protein. Toxicology (2002) 1.60
Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2011) 1.59
Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol (2007) 1.57
Alcohol use and hepatitis C. Hepatology (2002) 1.55
Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol (2004) 1.55
The impact of Medicaid managed care on hospitalizations for ambulatory care sensitive conditions. Health Serv Res (2005) 1.55
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54
Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation (2003) 1.54
Safety of cardiac catheterization in patients with end-stage liver disease awaiting liver transplantation. Am J Cardiol (2009) 1.53
Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J Hepatol (2008) 1.53
Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl (2011) 1.52
Outcomes with split liver transplantation in 106 recipients: the University of California, San Francisco, experience from 1993 to 2010. Arch Surg (2011) 1.51
Variation in care for nonmelanoma skin cancer in a private practice and a veterans affairs clinic. Med Care (2004) 1.51
Use of CT cholangiography to evaluate the biliary tract after liver transplantation: initial experience. Liver Transpl (2004) 1.50
Factors influencing liver transplant length of stay at two large-volume transplant centers. Liver Transpl (2009) 1.48
Expanding the donor pool: can the Spanish model work in the United States? Am J Transplant (2003) 1.48
Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl (2013) 1.46
A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis (2013) 1.46